Description
An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
Formal name: 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4H-1-benzopyran-4-one, monohydrochloride
Synonyms: Alvocidib|HL 275|HMR 1275|L-868,275
Molecular weight: 438.3
CAS: 131740-09-5
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Kinase Inhibitors|CDKs||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Cell Signaling||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS
